We are a globally operating Contract Development and Manufacturing Organisation (CDMO) headquartered in Germany. Our sites in Germany, France, Greece and Japan focus on the development and manufacturing of drug products (FDF) in the small molecule segment. Our manufacturing sites cover relevant technologies in sterile liquids, non-sterile liquids, and semi-solids, providing end-to-end services for our large base of (bio)pharma customers. Our development site in Greece is a one-stop shop for our partners offering a range of services to take products from inception to MA grant and supply.
Adragos Pharma raised undisclosed on October 1, 2021